


SOPHiA DDM™ BioPharma Solutions

Advance targeted therapy development by harnessing the power of data and multimodal analytics

Advances in **molecular and imaging techniques** have resulted in an **explosion of data**, providing an unprecedented opportunity to identify clinically relevant drug targets. Yet, deciphering and extracting subtle biomarker signatures from multiple data modalities and sources remains challenging.

The **cloud-based and decentralized SOPHiA DDM™ Platform** integrates data and algorithms, driving valuable insights to uncover biomarkers, identify requirement-matching cohorts, enhance clinical trial performance, and streamline the development of new drugs.

Data-driven solutions optimized for each stage of your drug development journey




Foster evidence-based decisions at critical stages of your value chain




Accelerate time-to-market for new therapies



Enhance target cohort identification



Increase clinical trial success rate





Improve ROI on drug development

Leverage the global footprint of the SOPHiA DDM™ Platform

1.3M

Genomic profiles¹ complemented by epidemiology data



Harness our data collaborations to accelerate precision medicine

Native Data

750+

Connected healthcare institutions² users of the SOPHiA DDM™ platform

Strategic Collaborations

AMCs

Growing strategic collaborations with academic medical centers (AMCs)

Sponsored Studies

Clinical studies

Observational real-world clinical studies such as DEEP-Lung-IV (NCT04994795) and UroCCR (NCT05404685)

Our collaboration with Memorial Sloan Kettering Cancer Center (MSK) is driving knowledge sharing and nurturing the advancement of precision oncology. With SOPHiA DDM™, you can harness MSK's proprietary comprehensive liquid biopsy and tumor sequencing tests, such as MSK-ACCESS® and MSK-IMPACT®, to bring more biomarker-driven clinical trials to the right patients.



Memorial Sloan Kettering Cancer Center

About SOPHiA GENETICS

SOPHiA GENETICS is a health tech company democratizing Data-Driven Medicine (DDM) to improve health outcomes and economics worldwide. By unlocking the power of new-generation health data for cancer and rare disease management, the SOPHiA DDM™ platform allows clinical researchers to act with precision and confidence. The company's innovative approach and patented machine learning-based algorithms enable a community of more than **750 institutions** to share knowledge. Together, SOPHiA GENETICS and its users are fostering a new era in healthcare.

Ready to Advance your Clinical Research?

Learn how we can work together to accelerate drug development.

Get in touch →



1. Since December 31, 2021. 2. Represents active customers who have generated revenue through the SOPHiA DDM™ platform usage or Alamut™ Visual Plus licenses as of September 30, 2022.

© 2023 SOPHiA GENETICS. All rights reserved. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

